Cardiology in Review, published by Lippincott Williams & Wilkins, is a prominent journal focused on advancing the field of cardiology and cardiovascular medicine. With a history of publication spanning from 1995 to 2024, the journal serves as an essential resource for researchers, healthcare professionals, and students alike, offering in-depth reviews and analyses on the latest developments, clinical practices, and research findings in cardiology. Despite being a traditional print journal, it maintains a commendable Q2 ranking in both cardiology and miscellaneous medicine categories as of 2023, reflecting its influence and rigor in the academic community, with a Scopus rank of #132 out of 387 in its field, placing it in the 66th percentile. The journal aims to bridge the gap between clinical practice and emerging research, promoting a deeper understanding and integration of innovative strategies in cardiovascular care. With its commitment to high-quality scholarship, Cardiology in Review remains a vital conduit for knowledge and dialogue within the evolving landscape of cardiovascular health.

CURRENT CARDIOLOGY REVIEWS, an esteemed journal published by BENTHAM SCIENCE PUBL LTD, is a pivotal resource in the field of cardiology and cardiovascular medicine. With an ISSN of 1573-403X and E-ISSN of 1875-6557, this journal presents comprehensive reviews that contribute significantly to the advancement of scientific knowledge and clinical practices in cardiology. Operating with open access options, CURRENT CARDIOLOGY REVIEWS is dedicated to bridging the gap between research and practice, thereby encouraging interdisciplinary collaboration and knowledge sharing. The journal has been instrumental in disseminating high-impact findings, consistently maintaining a Q2 category ranking in both Cardiology and Cardiovascular Medicine, as well as within the miscellaneous categories of Medicine, highlighting its relevance and respect in the academic community. Researchers, practitioners, and students alike will find valuable insights into contemporary cardiovascular issues, practices, and innovations that promote better patient outcomes. Based in the United Arab Emirates, CURRENT CARDIOLOGY REVIEWS encourages global contributions and reflects the latest advancements up to the year 2024, solidifying its role as an essential publication for those engaged in the quest for excellence in cardiovascular health.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, the esteemed publication of Elsevier Science Inc, stands as a premier platform for advancing knowledge in the field of cardiology and cardiovascular medicine. With an impressive impact factor reflecting its prominence—ranked Q1 in its category for 2023 and occupying the 4th position out of 387 in the Scopus listings, firmly placing it in the 99th percentile—this journal is essential for researchers, clinicians, and students alike. Since its inception in 1983, it has continuously provided a vital space for high-quality research and innovative clinical practices, driving forward our understanding of cardiovascular health. While access options are not open, the value of the cutting-edge articles published here cannot be overstated, as they foster collaboration and inform better patient care across the globe. As part of its ongoing commitment to excellence, the journal solicits submissions of original research, reviews, and clinical studies that contribute meaningfully to the field and engage its diverse readership.

HEART AND VESSELS is a prominent peer-reviewed journal published by SPRINGER, dedicated to advancing the fields of cardiology and cardiovascular medicine. With its ISSN 0910-8327 and E-ISSN 1615-2573, this esteemed journal encompasses a broad range of topics pertinent to heart health, vascular function, and associated therapies, making it an essential resource for researchers, clinicians, and healthcare professionals alike. Based in Japan and operating since 1985, HEART AND VESSELS has consistently maintained a Q2 ranking in the 2023 category quartiles, highlighting its relevance and impact in the cardio domain. Although it does not offer open access, the journal ensures high-quality publications that contribute significantly to the academic and clinical understanding of cardiovascular health. With over three decades of continuous scholarly contribution, HEART AND VESSELS serves as a vital platform for disseminating cutting-edge research and fostering innovative practices in the management of cardiovascular diseases.

Cardiovascular Diagnosis and Therapy, an esteemed journal in the field of Cardiology and Cardiovascular Medicine, is published by AME PUBLISHING COMPANY, based in Hong Kong, China. With an ISSN of 2223-3652 and an E-ISSN of 2223-3660, this open-access journal aims to present cutting-edge research that significantly advances diagnostic and therapeutic practices in cardiovascular health. Recognized for its impact, it holds a 2023 category quartile ranking of Q2 and is positioned at rank #124 out of 387 in Scopus, reflecting its noteworthy contribution to medical literature with a percentile of 68th. The journal welcomes contributions that span various aspects of cardiovascular research, including clinical trials, epidemiological studies, and innovative therapeutic approaches, making it a vital resource for researchers, practitioners, and students alike, committed to improving cardiovascular care.

Journal of Atherosclerosis and Thrombosis is a leading academic publication dedicated to advancing research in the fields of cardiovascular medicine, biochemistry, and internal medicine. Published by the Japan Atherosclerosis Society, this esteemed journal operates from its headquarters in Tokyo, Japan, and has been a vital resource in its area since its inception in 1994. With its robust impact in Cardiology and Cardiovascular Medicine, ranking in the top quartile (Q1) as of 2023, and a commendable standing in Internal Medicine and Biochemistry, the journal fosters an environment of innovation and discovery, showcasing significant studies and advancements that shape clinical practices and therapeutic approaches. Though not an open-access publication, it offers a wealth of insights to researchers, professionals, and students seeking to deepen their understanding of atherosclerosis and thrombosis. By continually featuring high-quality articles, the Journal of Atherosclerosis and Thrombosis plays an essential role in bridging the gap between research and practice, facilitating critical conversations that influence the future of cardiovascular health.

Netherlands Heart Journal is a premier academic publication dedicated to advancing knowledge in the field of cardiology and cardiovascular medicine. Published by BOHN STAFLEU VAN LOGHUM BV, this journal has established itself as a critical platform for researchers, professionals, and students seeking to explore groundbreaking findings and innovative practices in cardiovascular health. With an ISSN of 1568-5888 and E-ISSN 1876-6250, the journal boasts a respectable Q2 ranking in the Cardiology and Cardiovascular Medicine category, placing it in the top half of its field according to the 2023 quartiles. The Scopus ranking places it 130th out of 387 in the relevant category, indicating a commendable percentile rank of 66th, which attests to its influence and quality of published research. Spanning from 2005 to 2024, the journal endeavors to include a diverse array of topics, encompassing clinical practice, technological innovations, and public health considerations related to cardiovascular diseases. Researchers and practitioners are encouraged to engage with the journal's robust content, contributing to and benefiting from the collaborative effort to enhance cardiovascular health worldwide.

Acta Cardiologica Sinica is a distinguished journal dedicated to the advancement of cardiology and cardiovascular medicine, published by the Taiwan Society of Cardiology. Since its inception in 1988, this journal has provided a platform for researchers and clinicians to share cutting-edge findings and insights into cardiac health, cardiovascular diseases, and innovative treatment strategies. With an impressive Q3 classification in the Cardiology category for 2023, the journal is recognized for its contributions to the field, ranked #208 out of 387 in Scopus, placing it within the 46th percentile of medical journals. Although it currently does not offer open access options, it remains a valued resource for the global cardiovascular community. The journal's commitment to disseminating high-quality research papers, reviews, and case studies ensures that it plays a vital role in improving cardiovascular health practices and outcomes. For researchers, professionals, and students alike, Acta Cardiologica Sinica is essential reading for staying informed about the latest developments in cardiology.

PROGRESS IN CARDIOVASCULAR DISEASES is a leading journal in the field of cardiology and cardiovascular medicine, published by W B SAUNDERS CO-ELSEVIER INC. With an impressive impact factor that places it in the esteemed Q1 quartile of its category, this journal ranks among the top 32 out of 387 journals in its field, positioning itself in the 91st percentile. Since its inception in 1958 and continuing until 2024, it has been a prolific source of cutting-edge research, reviews, and clinical insights that contribute significantly to the understanding and treatment of cardiovascular diseases. Although it does not currently offer open access options, the journal's rigorous peer-review process ensures that all published content meets the highest standards of scientific excellence. As a key resource for researchers, practitioners, and students alike, PROGRESS IN CARDIOVASCULAR DISEASES serves as an indispensable tool for advancing knowledge and practice in cardiovascular health.

The JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, published by SAGE PUBLICATIONS INC, is a premier resource in the fields of cardiology and pharmacology, with an impressive impact factor reflective of its significant contributions to the scientific community. Established in 1996 and continuing through 2024, this journal is indexed in Scopus, achieving notable rankings, including Q2 in both Cardiology and Cardiovascular Medicine and Pharmacology. By fostering a multidisciplinary approach, it aims to improve pharmaceutical therapies and patient outcomes in cardiovascular health. Although not an open-access journal, it provides various subscription options to grant access to its cutting-edge research and reviews. As a vital platform for meaningful discourse and innovation in cardiovascular pharmacology, the journal attracts a diverse readership of researchers, professionals, and students, enhancing knowledge and advancing the field.